Amy Sam

Phase II Trial of Weekly Bortezomib in Combination With Rituximab in Relapsed or Relapsed and Refractory Waldenström Macroglobulinemia

Irene M. Ghobrial, Fangxin Hong, Ashraf Badros et al. · Journal of Clinical Oncology · 2010 · 165 citations · Full text

Medicine, Internal Medicine, Pharmacotherapy +16

Phase II trial of weekly bortezomib in combination with rituximab in untreated patients with Waldenström Macroglobulinemia

Irene M. Ghobrial, Wanling Xie, Ashraf Badros et al. · American Journal of Hematology · 2010 · 148 citations · Full text

Medicine, Hematology, Pharmacotherapy +14

Weekly bortezomib in combination with temsirolimus in relapsed or relapsed and refractory multiple myeloma: a multicentre, phase 1/2, open-label, dose-escalation study

Irene M. Ghobrial, Edie Weller, Ravi Vij et al. · The Lancet Oncology · 2011 · 97 citations

Medicine, Pharmacology, Pharmacotherapy +17

Safety and long-term immunogenicity of the two-dose heterologous Ad26.ZEBOV and MVA-BN-Filo Ebola vaccine regimen in adults in Sierra Leone: a combined open-label, non-randomised stage 1, and a randomised, double-blind, controlled stage 2 trial

David Ishola, Daniela Manno, Muhammed O. Afolabi et al. · The Lancet Infectious Diseases · 2021 · 95 citations · Full text

Veterinary Medicine, Immunology, Infectious Diseases +13

Safety and immunogenicity of the two-dose heterologous Ad26.ZEBOV and MVA-BN-Filo Ebola vaccine regimen in children in Sierra Leone: a randomised, double-blind, controlled trial

Muhammed O. Afolabi, David Ishola, Daniela Manno et al. · The Lancet Infectious Diseases · 2021 · 93 citations · Full text

Veterinary Medicine, Immunology, Infectious Diseases +14